Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: Prevalence and risk factors

Janghorbani, Mohsen; Rezvanian, Hassan; Kachooei, Ali; Ghorbani, Ahmad; Chitsaz, Ahmad; Izadi, F Farzad; Amini, Masoud

doi:10.1159/000497604

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reported that the advancing age increases the incidence of neuropathy. The average duration of diabetes in our study was 10 years which is not very long yet correlates well with previous reports [ 16 , 17 ]. Prolonged exposure of peripheral nerves to hyperglycemia in long standing diabetics predisposes them to development of neuropathy.…”

Section: Discussionsupporting

confidence: 92%

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Patel¹,

Mishra²,

Patel

et al. 2014

J Diabetes Metab Disord

View full text Add to dashboard Cite

BackgroundDiabetic peripheral neuropathy (DPN) is a common, symptomatic, long-term complication of diabetes mellitus. Many of the agents used to treat DN have not been compared with each other. This study was, therefore, undertaken to compare the efficacy and safety of carbamazepine, pregabalin and alpha-lipoic acid in diabetic neuropathy patients.MethodsThis was a prospective, observational study. The patients were categorized into three groups, Group I included those patients who were prescribed carbamazepine while group II included those on pregabalin and group III patients received alpha-lipoic acid. Each patient was followed up at every month for total duration of 6 months. Demographic details, presenting symptoms, history of diabetes, laboratory values pertaining to diabetes (Fasting blood sugar, Post prandial blood sugar and HbA1c) were recorded. Intensity of pain, using a visual analogue scale (VAS), diabetic neuropathy symptom (DNS) score and diabetic neuropathy examination (DNE) score were assessed at baseline and then at each monthly follow-up. Nerve conduction velocity (NCV) was also measured at baseline and then at the end of 3 and 6 months.ResultsA total of 101 patients were enrolled out of them 96 completed the study. Regarding VAS, the number of patients having pain was reduced substantially however, the speed and the quantum of this reduction were best in group II (pregabalin). Regarding DNS, also group II showed the best response in terms of number of patients as well as the speed of improvement. The results also imply that the relief from diabetic neuropathy (as per DNE score) is superior with pregabalin administration. However, no improvement in NCV was evident in any group.ConclusionResults of this study suggest that treatment with pregabalin gives faster and better improvement in diabetic neuropathy.

show abstract

Section: Discussionsupporting

confidence: 92%

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Patel¹,

Mishra²,

Patel

et al. 2014

J Diabetes Metab Disord

View full text Add to dashboard Cite

show abstract

“…However, the current study showed lower prevalence of DPN when compared to other studies reported from Iran, Nigeria, and Italy with DPN prevalence of 75.1%, 75%, and 82%, respectively [40][41][42]. The higher prevalence of those studies could be due to difference in study settings, tool used, and study design.…”

Section: Discussioncontrasting

confidence: 86%

Prevalence and Determinants of Peripheral Neuropathy among Type 2 Adult Diabetes Patients Attending Jimma University Medical Center, Southwest Ethiopia, 2019, an Institutional-Based Cross-Sectional Study

Abdissa

Hamba

Kene

et al. 2020

Journal of Diabetes Research

View full text Add to dashboard Cite

Background. Diabetes chronic complications are major causes of morbidity and mortality, among which diabetic peripheral neuropathy (DPN) stands out. One of the tools to screen DPN is the Michigan neuropathy screening instrument. However, there is no data compiled using this tool to assess the prevalence and its determinants in Jimma. So, the aim of this study was to assess the prevalence of DPN and its determinants among patients with diabetes mellitus at Jimma University Medical Center. Methods. A hospital-based cross-sectional study was conducted at Jimma University Medical Center on 366 type 2diabetic patients. Data were collected using pretested structured questionnaire and entered into EpiData 3.1 and exported to SPSS version 20 for analysis. Both bivariate and multivariate binary logistic regressions were employed to identify factors associated with DPN. A variable having a p value of < 0.25 in the bivariate model was subjected to multivariate analysis to avoid confounding variable’s effect. Adjusted odds ratios were calculated at 95% confidence interval and considered significant with a p value of ≤ 0.05. Results. The mean age of participants was 50.1±14.28 years. The study finding showed that the prevalence of DPN was 53.6% among study participants. According to the multivariate logistic regression age above 40 years (AOR=4.57; 95% CI: 1.50, 13.9), above 50 years (AOR=6.5; 95% CI: 2.24, 18.79), duration of diabetes above 5 years (AOR=3.06; 95% CI: 1.63, 5.77), duration above 10 years (AOR=7.1; 95% CI: 2.99, 17.28), physical inactivity (AOR=2.02; 95% CI: 1.14, 3.55), and smoking (current smoker AOR=7.96, 95% CI: 3.22, 19.64; former smoker (AOR=2.65; 95% CI: 1.22, 5.77) were independent predictors of DPN among study participants. Conclusion. Almost half of the study participants had DPN. Age above 40 years, diabetes duration of above 5 years, physical inactivity, and smoking were significantly associated with DPN. Early detection and appropriate interventions are important among patients with age above 40 years, physically inactive, smokers, and diabetes duration of above 5 years.

show abstract

“…The study showed that the most common affected group with decreasing of nerve conduction velocity and amplitude among all diabetic patients groups in the studied sample was the group of the longer duration of the disease. This finding agrees with most other studies conducted about the nerve conduction changes in diabetic patients like Tesfaye et al 25 , Barbosa et al 28 , Rajbhandari and Piya 29 , Janghorbani et al 30 , Charles et al 31 , and Malazy et al 32 . This is because of increased the chance of susceptibility to hyperglycemia deleterious complications with increase in the duration of the disease.…”

Section: Discussionsupporting

confidence: 92%

The Factors That Influence on Nerve Conduction in Diabetic Patients

Khudair¹,

Hamdan²,

Baqer³

2015

Basrah Journal of Surgery

View full text Add to dashboard Cite

The alteration in nerve conduction is considered one of the important complaints of patients who are suffering from diabetes mellitus nowadays. Therefore, we conduct this study which aimed to evaluate the nerve conduction velocity and amplitude in diabetic patients and assess the effects of the patients' age, severity and duration of diabetes on nerve conduction impairment. A case control study, the studied sample were 200 persons, 150 diabetic patients (93 males and 57 females) and the control group consisted of 50 participants (32 males and 38 females). All the patients attended the neurophysiology outpatient department of Al-Sader Teaching Hospital in Basrah city. The diabetic participants were selected at random from age, diabetes duration, and sex. Regarding the ages and exclusion criteria of the controls were ranged same as the diabetic. All participants were interviewed and a questionnaire form was filled prior to examination. Both the diabetic patients and the controls were subjected to the same electrophysiological and laboratory investigations. The results of the study showed a significant decrease in nerve conduction velocity and amplitude in diabetic patients comparing to controls in all the examined nerves. Furthermore, there was a significant association between advancing age and longer-duration of diabetes with the reduction of conduction velocity and amplitude. Also, a significant inverse correlation between increased severity of diabetes disease (HbA1c level) and decreasing of both conduction velocity and amplitude. However, the study demonstrated no statistical significant difference between patients and controls regarding the gender. In conclusion, the age of the patients, duration of the disease and the severity of diabetes (hyperglycemia control) are playing a crucial role as risk factors in developing of peripheral neuropathy in diabetic patients.

show abstract

Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: Prevalence and risk factors

Cited by 8 publications

References 0 publications

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Prevalence and Determinants of Peripheral Neuropathy among Type 2 Adult Diabetes Patients Attending Jimma University Medical Center, Southwest Ethiopia, 2019, an Institutional-Based Cross-Sectional Study

The Factors That Influence on Nerve Conduction in Diabetic Patients

Contact Info

Product

Resources

About